NAD+ Providers, Compared on Price and Pharmacy Transparency
38 providers, each read directly off its own site — 10 publish no price for NAD+ at all, and only 13 name their pharmacy and state a regulatory category.
On this page▾
/ The board
Any paid placement on this board is marked Partner and listed first, as a disclosed commercial position — within that group, and separately within every other row, every provider is still ranked on the criteria printed on this page, never anything else (see disclosure). Full write-ups below.
“Flat price” means one all-in monthly figure with no separate membership or lab fee; any other pricing chip names the mechanic that gets in the way, or that the provider has not stated one. “Labs” is whether bloodwork is required, optional, not used, or not stated on the provider's own site. The pharmacy chip states a facility type (503A pharmacy, 503B facility) only where the provider publishes one we could cite; “Not disclosed” means we read their site and they do not say, and “Unverified” means nobody has checked this company's pharmacy sourcing yet — of the 38 providers on this board, 13 publish a facility type at all. Every provider here includes the clinician consult. Each row above shows the exact date its price was checked on that provider's own site — prices can change without notice.
Every provider read live off its own site by August 2026, ranked by the same criteria as the board above: pharmacy disclosure first, then advertised price, low to high. #1 is our top pick on those criteria — filter to see the rest a different way.
Showing our top 10 of 38, by pharmacy disclosure then price
1
Care Bare Rx
Care Bare Rx names four real pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx) and states a network-level regulatory-category claim in its FAQ — but its own dedicated NAD+ Therapy product page publishes no price.
CB
No price is published on Care Bare Rx's own /products/nad-therapy page — a real gap, honestly recorded rather than estimated.
NAD+ Therapy ships through the same pharmacy network as Care Bare Rx's other compounds. Its own /faq page states, "...regulatory standards established by: State boards of pharmacy, which regulate all 503A pharmacies..." — a network-level claim, not pinned to one specific pharmacy per compound. Two of its four named pharmacies carry real, disclosed FDA warning-letter history — a knock, not a disqualifier, per this site's standing treatment of every other row that names the same vendors.
Strengths
Names four real pharmacy partners directly, with a network-level regulatory-category claim stated in its own FAQ
Transparent pricing language elsewhere on the site ("no insurance required") even though this specific product page omits a number
A real, dedicated NAD+ Therapy product page exists
Trade-offs
No price is published anywhere on the NAD+ Therapy page
The regulatory-category claim is network-level, not pinned to which of its four pharmacies actually fills a NAD+ order
Two of its four named pharmacy partners have disclosed FDA warning-letter history (Belmar Pharma Solutions, 2023; Strive Pharmacy, 2022, closed out 2026) — a real knock worth knowing
Telos Rx names its primary compounding pharmacy (VialsRX) directly and states a regulatory category for it, unhedged, elsewhere on its site — and prices NAD+ Nasal Spray with a real published discount mechanism: $249 dropping to $116/mo on a longer plan.
TR
Telos Rx's own /nad-nasal-spray page states "As low as $249 → $116/mo," with pricing scaled to plan length and cancelable anytime, per its own site.
NAD+ Nasal Spray ships through the same named pharmacy as Telos Rx's semaglutide row: its own semaglutide page states explicitly, "Telos RX prescribes compounded semaglutide through a licensed US 503A pharmacy," naming VialsRX (Houston, TX). A secondary partner, Jungle Jim's Pharmacy, is named for non-sterile/oral forms, with a disclosed 10-state licensing gap.
Strengths
Names its primary compounding pharmacy (VialsRX) directly and states a regulatory category for it, unhedged, elsewhere on its site
Publishes a real discount mechanism ($249 down to $116/mo) rather than a single unexplained "starting at" number
States plainly that the subscription is cancelable anytime with no penalties
Trade-offs
The lowest $116/mo rate requires the longest available plan; a shorter commitment costs closer to the $249 figure
A secondary fulfillment pharmacy (Jungle Jim's Pharmacy) discloses it cannot serve 10 named states — a real coverage gap for an order routed there
No dose-tier ceiling beyond the published plan-length pricing
Breeze Meds prices NAD+ Injections "starting at $169" — the lowest published starting price among this board's six partner rows — and names the same four-pharmacy network as Care Bare Rx and Synergy Rx, though neither "503A" nor "503B" appears anywhere on its site.
BM
Breeze Meds' own site states NAD+ Injections "Starting at $169" — a floor, not a stated flat rate; no dose-tier breakdown is published.
NAD+ Injections ship through the same four-pharmacy network as Care Bare Rx and Synergy Rx: its own FAQ names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx directly, with phone numbers — confirming a shared fulfillment network across all three storefronts. Neither "503A" nor "503B" appears anywhere on the live site, confirmed against the full rendered page text.
Strengths
The lowest published NAD+ starting price among this board's six partner rows ($169)
Names four pharmacy partners directly, with phone numbers, in its own FAQ
Part of an already-reviewed catalogue on this site (tirzepatide, semaglutide)
Trade-offs
"Starting at" pricing only — no dose-tier breakdown or ceiling is published
Neither "503A" nor "503B" appears anywhere on the live site, despite naming four specific pharmacies
No stated dosing frequency or format detail beyond "Injections"
Synergy Rx prices NAD+ Injection "starting at $275" and names the same four pharmacy partners Care Bare Rx uses (Belmar, Strive, Epiq Scripts, Casa Pharma Rx) — but neither "503A" nor "503B" appears anywhere on its own site.
SR
Synergy Rx's own site states NAD+ Injection "Starting at $275" — the same starting-price framing it uses across its whole compound catalogue.
NAD+ Injection ships through the same pharmacy network as Care Bare Rx and Breeze Meds — Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx, confirming a shared fulfillment network across all three storefronts. Its own Terms of Use say only that medications "are dispensed by independent third-party pharmacies"; neither "503A" nor "503B" appears anywhere on the site checked.
Strengths
Names four real pharmacy partners, the same network independently confirmed across two sibling storefronts on this board
A published, if floor-only, starting price
Part of an already-reviewed catalogue on this site (sermorelin)
Trade-offs
"Starting at" pricing only — no dose-tier breakdown or ceiling is published
Neither "503A" nor "503B" appears anywhere on the site, despite naming four specific pharmacies
No stated dosing frequency or format detail beyond "Injection"
Strut Health advertises compounded NAD+ injections for cellular energy and recovery, but — as with the rest of its product line — names no specific pharmacy and publishes no price for NAD+ anywhere on the live site.
No price is published for NAD+ Therapy on Strut Health's /peptides page; the site states only that it is a compounded injectable, shipped from a U.S. pharmacy.
NAD+ Therapy runs through the same telehealth-plus-unnamed-pharmacy model as Strut Health's tirzepatide and sermorelin rows. Its own Terms state a patient may direct a prescription "to the pharmacy of your choice," and its Telemedicine Consent separately references an unnamed "Strut Health's partner pharmacy" — no single pharmacy is named anywhere on the site, and neither "503A" nor "503B" appears anywhere checked.
Strengths
A real, live compounded NAD+ product, described directly on its own /peptides page
PCAB- and ACHC-accredited compounding credentials shown in the site footer
Free, discreet shipping, per its own site — the same claim as its other compounds
Trade-offs
No price is published for NAD+ anywhere on the live site
No pharmacy is named anywhere on the site, and neither "503A" nor "503B" appears anywhere checked
No dosing frequency or format detail beyond "injections" is published on the page
Oak sells a combined "NAD+ & Glutathione" product, but — like the rest of its catalogue — publishes no price and names no pharmacy anywhere on the pages we could reach.
OA
No price is published for Oak's "NAD+ & Glutathione" offering — the product exists as a clickable checkout link on its homepage, with no descriptive price, dosing, or sourcing detail on the page itself.
NAD+ is bundled with Glutathione as a single combined offering, rather than sold as its own standalone product — a different shape from most peers on this board. Its own site uses only generic "licensed U.S. compounding pharmacies" language; no pharmacy is named, and neither "503A" nor "503B" appears anywhere reached.
Strengths
A real, live checkout path exists for the combined NAD+ & Glutathione product
Simple one-click access from the homepage, no separate product page to hunt for
Part of a broader, already-reviewed catalogue on this site (tirzepatide, semaglutide)
Trade-offs
No price is published anywhere for this product
No pharmacy is named anywhere on the pages checked, and neither "503A" nor "503B" appears
Sold only as a bundled NAD+-plus-Glutathione product — a reader who wants NAD+ alone has no way to confirm from the site whether that's possible
RxPepsDirect names its compounding pharmacy (Optimal Balance Pharmacy, in Texas), together with a stated regulatory category for it, directly on the same product pages that state price — the clearest pharmacy-plus-price pairing of any row on this board — and sells NAD+ by the milligram/milliliter rather than a monthly subscription.
RX
RxPepsDirect prices NAD+ Injectable at "$100/1000mg" and NAD+ Nasal Spray at "$150/15ml" — a per-unit, cash-pay price rather than a recurring monthly subscription, the same shape as the rest of its peptide catalogue.
NAD+ ships through the same named pharmacy as RxPepsDirect's other compounds: its own product pages state directly, "dispensed by Optimal Balance Pharmacy," described as "a 503A pharmacy in Texas" — naming both the pharmacy and its state on the exact page that also states the price. It also states every batch is tested by Eagle Analytical for sterility and endotoxin, a lab-testing disclosure no other provider on this roster makes.
Strengths
Names its compounding pharmacy (Optimal Balance Pharmacy) and states a regulatory category for it on the SAME page that states the price — the clearest pairing of any row here
States independent third-party batch testing (Eagle Analytical, sterility and endotoxin) — a disclosure no other row on this board makes
A la carte, per-unit pricing rather than a recurring subscription — no ongoing commitment to cancel
Trade-offs
No bundled telehealth consult in the same sense as a monthly-subscription competitor — this is closer to a compounding pharmacy's direct order form
Per-unit pricing ($100/1000mg, $150/15ml) takes more work to compare against a competitor's monthly figure than a flat subscription price would
No stated dosing guidance beyond the product listing itself
EOS Health publishes two NAD+ formats at two different starting prices — nasal spray from $111.75/mo, injection from $134.25/mo — and names five pharmacy partners directly with a stated regulatory category, the most specific pharmacy disclosure of any row on this board.
EH
EOS Health's own cellular-anti-aging page states "From $134.25/mo" for NAD+ Injection and "From $111.75/mo" for NAD+ Nasal Spray. Both are floor prices; no dose-tier ceiling is published for either form.
NAD+ runs through the same pharmacy-disclosed model as EOS Health's other compounds: its own Clinical & Pharmacy Partners page names five pharmacies directly with a stated regulatory category, and its product pages state, "This medication is compounded by a licensed 503A pharmacy in accordance with Section 503A of the Federal Food, Drug & Cosmetic Act."
Strengths
Names five pharmacy partners directly, by name and city, with a stated regulatory category — the most specific pharmacy disclosure of any row on this board
Offers a choice of two delivery forms, each with its own published starting price
24/7 provider support included at no extra cost, per its own site
Trade-offs
Both prices are "from" floors — no dose-tier ceiling is published for either form
The nasal-spray and injection prices differ by over $22/mo, and the page does not explain what drives the gap
PreventiveMD prices NAD+ "as low as $119/mo, all-in" — explicitly billed as an all-inclusive figure rather than a bare floor — and states a direct, unhedged regulatory-category claim on its homepage, though no specific pharmacy is named.
PR
PreventiveMD's own /protocols/nad-plus page states NAD+ "As low as $119/mo, all-in" — the same "all-in" framing this company uses for its other compounds, meaning the figure is presented as inclusive of standard program costs rather than a bare drug-only price.
NAD+ runs through the same all-in pricing and disclosure model as PreventiveMD's other compounds. Its own homepage states, under a "100% U.S.-compounded peptides" heading, "We work exclusively with state-licensed, U.S.-based 503A compounding pharmacies" — unhedged, though no specific pharmacy is named by name anywhere checked.
Strengths
States a direct, unhedged regulatory-category claim on its own homepage
Prices are explicitly framed "all-in" rather than a bare floor that excludes program costs
Labs are not required to start, per its own FAQ — a lower barrier to entry than most peers on this board
Trade-offs
"As low as" pricing — the all-in framing does not mean it is a flat rate; a ceiling is not published
No specific pharmacy is named by name anywhere checked (protocol pages, homepage, or its Subscription, Cancellation & Refund Policy)
No dosing frequency detail beyond the monthly price is published
Precision Telemed names its compounding pharmacy (Rush Pharmacy) and states a regulatory facility category for it across its site — the same disclosure that already anchors its tirzepatide and sermorelin rows — and prices NAD+ at a flat $139.99/mo with no promo hedge.
Precision Telemed's site states NAD+ at a plain "$139.99/mo," with no floor-price or dose-tier language attached — the same flat-figure shape as several of its other product lines.
NAD+ runs through the same telehealth-plus-named-pharmacy model as Precision Telemed's tirzepatide and sermorelin programs: physician consult included, medication filled by Rush Pharmacy, which the company states directly is "a licensed 503A compounding pharmacy" on its other product pages.
Strengths
Names its compounding pharmacy (Rush Pharmacy) and states a regulatory facility category for it — a disclosure carried across its whole site, not just one product
A flat, unhedged $139.99/mo price with no visible dose-tier breakdown
States plainly, in its own FAQ, availability in all 50 states with no exclusions listed
Trade-offs
The NAD+ price was captured from the general site rather than a dedicated NAD+ product page — no dose or dosing-frequency detail is published for this specific compound
No dietitian or nurse is named specifically; support is physician-led, not clinical nutrition or nursing
No published ceiling if a provider recommends a higher dose or frequency
YourHealthRx states, unhedged, exactly which federal regulatory category its compounding pharmacies fall under, and prices NAD+ "as low as $150/mo" on a dedicated compound page — though, like the rest of its catalogue, no specific pharmacy is named by name.
YO
YourHealthRx's own /compounds/nad/ page states "As low as $150/mo" — a floor, not a stated flat rate; no dose-tier breakdown is published.
NAD+ has its own dedicated compound page, following the same template as YourHealthRx's other products. Its compound pages state directly, unhedged, "YourHealthRx connects patients with independently licensed clinicians and partner 503A compounding pharmacies" — no specific pharmacy is named by name anywhere checked.
Strengths
States a direct, unhedged regulatory-category claim on its own compound pages
A real, dedicated NAD+ page, following the same consistent template as the rest of its catalogue
A mid-range starting price with no separate membership fee layered on top
Trade-offs
"As low as" pricing only — no dose-tier breakdown or ceiling is published
No specific pharmacy is named by name anywhere checked
Willow prices NAD+ at a flat $199/mo and names three partner pharmacies directly, with full addresses and phone numbers, in its Terms and Conditions — more specific than most peers on this board — though neither is tied to a stated regulatory category.
Willow's own /nad-plus page states a plain "$199/mo" figure, with no floor-price hedge or visible dose tier.
NAD+ runs through the same three-pharmacy network as Willow's other compounds. Its Terms and Conditions name Red Rock Home Pharmacy, Epiq Pharmacy, and The Pharmacy Hub directly under a "Partner Pharmacy" heading — but neither "503A" nor "503B" appears anywhere in the site's rendered content, checked across every page.
Strengths
A flat, unhedged $199/mo price with no visible dose-tier breakdown
Names three partner pharmacies directly, each with a full street address and phone number
Consistent, specific pharmacy disclosure across its whole product line
Trade-offs
Despite naming three pharmacies by name, neither "503A" nor "503B" appears anywhere on the site — the regulatory category itself stays unconfirmed
No dosing frequency or format detail beyond "NAD+" is published on the page
No stated ceiling if a provider recommends a different dose
Vytora Health prices NAD+ Injection at $249/mo month-to-month or $200/mo on a 3-month plan, and names two fulfillment pharmacies directly by name and address — though neither is tied to a stated regulatory category.
VH
Vytora's own /nad page states NAD+ Injection at "$249/mo (1-month) / $200/mo (3-month plan)" — the standard prepay-discount shape, with both figures published rather than only the lower one.
NAD+ Injection ships through the same two-pharmacy network as Vytora's other compounds: "Vials Pharmacy" (Houston, TX) and "Hallandale Pharmacy" (Fort Lauderdale, FL), both named directly on its /about page — but neither "503A" nor "503B" appears anywhere checked, including its Terms of Service.
Strengths
Publishes both the month-to-month price ($249/mo) and the 3-month prepay price ($200/mo), rather than only the promotional figure
Names two fulfillment pharmacies directly, with full addresses, on its own /about page
A real, dedicated NAD+ product page with a clear price structure
Trade-offs
The lower $200/mo figure requires a 3-month prepay to unlock; a no-commitment customer pays $249/mo
Neither named pharmacy is tied to "503A" or "503B" anywhere on the site, including the Terms of Service
Hallandale Pharmacy is the same pharmacy PepHaūs names for its own NAD+ line — a shared white-label vendor pattern worth knowing, not itself disqualifying
Big Easy Weight Loss sells NAD+ Therapy bundled with sermorelin as one 8-week package ($267+) rather than as a standalone monthly subscription, and names six pharmacies directly, each with its own stated 503(a)/503(b) category and state-exclusion list — the most individually-sourced pharmacy detail of any row on this board.
BE
Big Easy Weight Loss's own /products/nad-therapy page states "Starting at $267 for 8 weeks," bundled together with sermorelin as one package rather than sold as a standalone NAD+ product — a different shape from every other row on this board.
NAD+ Therapy is sold as part of an 8-week bundle with sermorelin, not a standalone subscription. Its own /pharmacy-partners page names six pharmacies directly, each with its own stated category and state-exclusion list — more individually-sourced pharmacy detail than any other provider on this roster, even though no single company-wide category is stated.
Strengths
Names six pharmacies directly, each with its own stated 503(a)/503(b) category and state-exclusion list — the most individually-sourced pharmacy detail of any row on this board
A published starting price for a defined 8-week program, not an open-ended subscription
Transparent about the bundle: NAD+ Therapy is sold together with sermorelin, not marketed as a standalone product it isn't
Trade-offs
Not sold as a standalone NAD+ product — a reader who wants NAD+ alone, without sermorelin, cannot confirm from the site that's an option
"Starting at" pricing for the bundle — no per-compound price breakdown is published
Six different pharmacies with six different state-exclusion lists makes coverage harder to confirm than a single named pharmacy would
AquaVita NextGen prices NAD+ at a flat $599 — the highest single published NAD+ price on this board — through its own shop page, which names no pharmacy and states only generic "compounded by a licensed pharmacy" language.
AN
AquaVita NextGen's own shop page states NAD+ (product listing "NAD-10") at a plain "$599" figure, with no visible subscription framing — read as a single order price rather than a recurring monthly rate.
NAD+ sells as a straightforward e-commerce product through AquaVita NextGen's shop, rather than a telehealth subscription. Its own shop page states only, "This medication is compounded by a licensed pharmacy and is not FDA-approved" — no pharmacy is named by name anywhere checked, and neither "503A" nor "503B" appears.
Strengths
A plainly stated, unhedged $599 price with no hidden membership fee layered on top
States directly, on the product page itself, that the medication is compounded and not FDA-approved, rather than implying otherwise
A straightforward e-commerce checkout, not a multi-step telehealth funnel
Trade-offs
The highest single published NAD+ price on this board
No pharmacy is named by name anywhere checked, and neither "503A" nor "503B" appears anywhere on the site
Unclear from the page whether $599 is a one-time or recurring charge
PepHaūs is the only row on this board whose own site names, on the same page, both a specific pharmacy for NAD+ (Hallandale Pharmacy) and a stated regulatory category for it — but its dedicated /nad page itself publishes no price.
PS
No price is published on PepHaūs's own /nad product page — a real gap, honestly recorded rather than guessed at.
PepHaūs's own /how-it-works page states directly, "NAD+, sermorelin, and glutathione are filled by Hallandale Pharmacy," describing it, unhedged, as a "U.S.-licensed 503A compounding pharmacy" — naming both the specific pharmacy AND the category, on the same page, for NAD+ by name.
Strengths
Names the specific pharmacy (Hallandale Pharmacy) that fills NAD+ AND states a regulatory category for it on the same page — the clearest pairing of any row on this board
A real, live, dedicated /nad product page exists, not just a mention buried in a general compound list
Consistent, specific pharmacy disclosure across its whole product line
Trade-offs
No price is published anywhere on its dedicated NAD+ page
No dosing frequency or format detail beyond "NAD+" is published
Eden sells NAD+ in three formats — injections, nasal spray, and a face cream — at three different prices, and owns its own compounding pharmacy (Eden Pharmacy), though that facility's regulatory designation is only stated in a linked press release, never on eden.health itself.
Eden's own site lists NAD+ Injections "from $119 first month," NAD+ Nasal Spray at "$112 first month then $127/mo," and a standalone NAD+ Face Cream at a flat "$84/mo." Each format has its own price; none states a dose ceiling beyond the first-month figure.
Eden names and links its own pharmacy, Eden Pharmacy, in its site footer. That pharmacy's own footer in turn links a PR Newswire release stating Eden "owns its own 503A compounding pharmacy — Eden Pharmacy, formerly Contigo Compounding" — a real, independently-indexed acquisition, but that facility's regulatory designation is never stated in first-party text on eden.health, tryeden.com, or edenpharmacy.com.
Strengths
Genuinely owns its own compounding pharmacy (Eden Pharmacy, formerly Contigo Compounding) rather than reselling a third party's
Offers three delivery formats at three published prices — injections, nasal spray, and a topical face cream
The nasal-spray listing states both a first-month and an ongoing monthly rate, rather than hiding the increase
Trade-offs
That facility's regulatory designation is stated only in a linked third-party press release, never in first-party text on any of its own sites
Two of three formats (injections, nasal spray) quote a first-month rate that increases or is left open-ended — read the fine print before signing up
No dose-tier ceiling is published for the injectable form
The lowest published NAD+ starting price on this roster ($93/mo) in either injectable or nasal-spray form — but, like its tirzepatide and sermorelin rows, CoreAge names no pharmacy and states no 503A/503B category.
CoreAge's own site lists both "NAD+ Injectable" and "NAD+ Nasal Spray" as "Starting at $93 per month," with no dose-tier breakdown or ceiling published for either form.
Both NAD+ formats route through the same cash-pay telehealth flow as CoreAge's tirzepatide and sermorelin programs: a physician-reviewed intake, medication described only as "compounded in the USA" and shipped from "trusted partner pharmacies" — no pharmacy named, no 503A/503B category stated anywhere we could find.
Strengths
Lowest published NAD+ starting price on this roster, in either injectable or nasal-spray form ($93/mo)
Offers a choice of two delivery forms (injectable, nasal spray) at the same starting price
24/7 provider support and a patient community are included per its own product pages, the same as its other compounds
Trade-offs
"Starting at" pricing only — no dose-tier breakdown or ceiling is published for either NAD+ form
No pharmacy is named and no 503A/503B category is disclosed anywhere on the live site
Lttl prices all three NAD+ formats — injectable, nasal spray, oral liquid — identically at "plans start at $129/mo," and its own Terms of Service name four real partner pharmacies by name and address, though neither ties any of them to a stated regulatory category.
LT
Lttl's homepage states "Plans start at $129/mo" identically for NAD+ Injectable, NAD+ Nasal Spray, and NAD+ Oral Liquid — one floor price covering all three delivery formats, no per-format breakdown.
Lttl offers NAD+ in three formats at the same starting price. Its own Terms of Service name four partner pharmacies directly, with street addresses and phone numbers — but neither "503A" nor "503B" appears anywhere on the live site, checked directly, so the regulatory category stays unconfirmed despite the specific pharmacy names.
Strengths
Offers three delivery formats (injectable, nasal spray, oral liquid) at one published starting price
Names four partner pharmacies directly, with street addresses and phone numbers, in its own Terms of Service
24/7 provider access bundled into every plan, per its own site
Trade-offs
"Plans start at" pricing only — no dose-tier breakdown or ceiling is published for any of the three formats
Despite naming four pharmacies by name, neither "503A" nor "503B" appears anywhere on the site — the regulatory category itself stays unconfirmed
Requires a prepay plan to unlock the quoted rate, per the same mechanism as its other compounds
TelePeptide prices NAD+ "starting at $129/mo," but that rate requires an annual prepay commitment — the most demanding commitment mechanism of any NAD+ row on this board — and the site names no specific pharmacy anywhere.
TE
TelePeptide's own /programs page states NAD+ "Starting at $129/mo with annual prepay" — the lock-in required to see that number is stated directly on the same page, not buried.
NAD+ runs through the same generic-pharmacy disclosure as TelePeptide's other compounds. Every page checked — the homepage, /pricing, and its Terms — describes fulfillment only generically as "licensed compounding pharmacies." No specific pharmacy is named, and neither "503A" nor "503B" appears anywhere on the site.
Strengths
States the annual-prepay requirement directly next to the price, rather than hiding it behind a lower advertised number
A real, itemized "peptide wellness" program page, not a buried mention
Consistent pricing structure across its product line
Trade-offs
The $129/mo rate requires a full annual prepay — the most demanding commitment mechanism of any NAD+ row on this board
No pharmacy is named anywhere on the site, and neither "503A" nor "503B" appears anywhere checked
No dose-tier ceiling or month-to-month alternative is published
Alternate Health Club prices NAD+ Injectable at a flat $140/mo, and its own Terms & Conditions state a regulatory-category claim — but only for its "affiliate pharmacy partners" generically, never naming a specific pharmacy.
AH
Alternate Health Club's own product page states NAD+ Injectable at a plain "$140/mo," with no visible dose-tier hedge.
NAD+ Injectable runs through the same generic regulatory-category disclosure as Alternate Health Club's other compounds. Its Terms & Conditions state medication is dispensed by "one of AHC's affiliate pharmacy partners, each of which is a licensed 503A compounding pharmacy" — a category claim, but no specific pharmacy is named by name anywhere checked.
Strengths
A flat, unhedged $140/mo price with no visible dose-tier breakdown
States a regulatory-category claim for its pharmacy network in its own Terms & Conditions
A real, dedicated NAD+ Injectable product page on the live site
Trade-offs
The regulatory-category claim covers "affiliate pharmacy partners" generically — no specific pharmacy is named by name anywhere checked
No dosing frequency detail beyond the monthly price is published
Belle Health prices NAD+ "from $149/mo" and names four pharmacy partners directly by name in its Terms of Service — more specific than most peers on this board — though none is tied to "503A" or "503B" anywhere on the site.
BH
Belle Health's own /treatments/longevity/nad-plus page states "From $149/mo," with no dose-tier breakdown or ceiling published.
NAD+ ships through the same four-pharmacy network as Belle Health's other compounds. Its Terms of Service state, "Prescription medications are dispensed by the following licensed pharmacy partners: BPI Labs, Inc. VitalRx Pharmacy The Pharmacy Hub Olympia Pharmaceuticals" — four named pharmacies, but neither "503A" nor "503B" is stated for any of them anywhere on the site.
Strengths
Names four pharmacy partners directly, by name, in its own Terms of Service — more specific than most peers on this board
A real, dedicated NAD+ longevity product page on the live site
Consistent pharmacy disclosure across its whole product line
Trade-offs
"From" pricing only — no dose-tier breakdown or ceiling is published
Despite naming four pharmacies, neither "503A" nor "503B" is stated for any of them anywhere on the site
Requires an auto-refill subscription to maintain the quoted rate, per the same mechanism as its other compounds
Yucca Health prices NAD+ "starting at $158/mo" on a dedicated product page, but — like its tirzepatide and sermorelin rows — names no pharmacy anywhere on the site, only generic "U.S. Licensed Pharmacies" language.
YH
Yucca's own /treatments/nad/ page states "Starting at $158/mo," with no dose-tier breakdown or ceiling published.
NAD+ has its own dedicated product page, unlike some peers that bury the compound in a general list. The site describes fulfillment only generically as "U.S. Licensed Pharmacies," repeated across its tirzepatide, semaglutide, and sermorelin pages — no specific pharmacy is named anywhere checked, and neither "503A" nor "503B" appears.
Strengths
A real, dedicated NAD+ product page, not a buried mention inside a general list
A mid-range starting price with no separate membership fee layered on top
Consistent pricing structure and copy across its whole product line
Trade-offs
"Starting at" pricing only — no dose-tier breakdown or ceiling is published
No pharmacy is named anywhere on the site, and neither "503A" nor "503B" appears anywhere checked
Fridays prices NAD+ at $179/mo on its quarterly plan — the same prepay-for-discount mechanism its tirzepatide row already documents — and its Help Center names four accredited partner pharmacies with a stated regulatory category, more disclosure than most rows here.
FR
Fridays' own /longevity page states a "Quarterly price" of $179/mo for NAD+. This page did not surface a separate one-month figure for NAD+ specifically, so $179/mo is recorded as the confirmed prepay rate, not assumed to be the standing month-to-month price.
NAD+ ships through the same pharmacy network as Fridays' other compounds: its own Help Center states "All partner pharmacies are 503A-accredited," and its Terms & Conditions name four specific pharmacies by name and address.
Strengths
Its own Help Center states, unhedged, exactly which federal regulatory category all its partner pharmacies are accredited under
Names four specific partner pharmacies directly, by name and address, in its Terms & Conditions — more disclosure than most rows on this board
Registered dietitian support is bundled into its plans, per its own site (the same feature already documented on its tirzepatide row)
Trade-offs
$179/mo is a quarterly-prepay figure; the page did not surface a separate month-to-month NAD+ price for comparison
Requires a 3-month prepay to unlock the quoted rate, per the same mechanism as its other compounds
No published dose or frequency detail specific to NAD+
HealthSource prices NAD+ Nasal Spray at a flat $179/mo and NAD+ Injection from $299/mo — the highest injectable NAD+ price on this board — and its product pages state "the partner 503A pharmacy" as a category claim, without ever naming the pharmacy itself.
HE
HealthSource's own product pages state NAD+ Nasal Spray at a flat "$179/mo" and NAD+ Injection at "From $299/mo," its own two-tier way of pricing the same compound by delivery form.
NAD+ ships through the same disclosure pattern as HealthSource's other compounds: its product pages state, "the partner 503A pharmacy will prepare your medication and ship it directly to your door" — a category claim, but no specific pharmacy is named by name anywhere checked.
Strengths
States a direct regulatory-category claim on its own product pages, even without naming the specific pharmacy
The nasal-spray form is a flat, unhedged $179/mo with no dose-tier hedge
Offers a choice of two delivery formats at two clearly published prices
Trade-offs
The injectable form is the most expensive published NAD+ starting price on this board ("From $299/mo")
No specific pharmacy is named by name anywhere checked — only "the partner 503A pharmacy," unnamed
Requires an auto-refill subscription to maintain the quoted rate, per the same mechanism as its other compounds
BluefitMD states, unhedged, exactly which federal regulatory category its licensed pharmacies fall under — a direct category claim repeated on two separate pages — and prices NAD+ Injection "as low as $199/mo," though no specific pharmacy is named by name.
BluefitMD's own site prices NAD+ Injection "as low as $199/mo" — a floor, not a stated flat rate; no dose-tier breakdown is published.
NAD+ runs through the same regulatory-category disclosure as BluefitMD's other compounds: its /about page states, unhedged, "BluefitMD connects you with licensed, U.S.-based 503A pharmacies that are state-regulated and audited for safety and quality," repeated on /safety-info — though no specific pharmacy is named by name anywhere on the site.
Strengths
States a direct, unhedged regulatory-category claim on two separate pages, repeated for this compound
A published, if floor-only, starting price
Consistent disclosure language across its whole product line, not invented for this one compound
Trade-offs
"As low as" pricing only — no dose-tier breakdown or ceiling is published
No specific pharmacy is named by name anywhere on the site, only "a licensed pharmacy in our network"
Requires a prepay plan to unlock the quoted rate, per the same mechanism as its other compounds
Rylo Health prices NAD+ at $183/mo on a prepay plan or $219 month-to-month, and names a specific fulfillment pharmacy (VialsRX) directly — though its site never ties that pharmacy to a stated regulatory category in the same sentence.
RH
Rylo Health's own product page states NAD+ at "$183/mo, or $219 monthly" — a prepay-discounted rate next to the standing month-to-month price, published together rather than hiding the higher figure.
NAD+ ships through the same VialsRX fulfillment pharmacy as Rylo Health's other compounds, named directly with address and phone number — but the site separately describes compounding only generically as "licensed 503A compounding pharmacies," never tying VialsRX itself to that category in the same statement.
Strengths
Publishes both a prepay-discounted rate ($183/mo) and the real month-to-month rate ($219/mo) on the same page, rather than only the promotional number
Names its fulfillment pharmacy (VialsRX) directly, with a full address and phone number
A real, dedicated NAD+ product page, not a buried mention
Trade-offs
The lower $183/mo figure requires a prepay commitment to unlock; a no-commitment customer pays $219/mo
VialsRX is named, but never explicitly tied to the site's separate "503A" claim in the same statement
No dose-tier ceiling beyond the two published monthly rates
VIV RX prices NAD+ at a flat $239 and names four fulfillment pharmacies directly, with address and phone number — more specific pharmacy detail than most peers on this board — though none is tied to "503A" or "503B" anywhere on the site.
VIV RX's own site states NAD+ at a plain "$239" figure, with no visible dose-tier breakdown or subscription framing distinguishing it from a one-time price.
NAD+ ships through the same four-pharmacy network as VIV RX's other compounds: Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx, named directly on a shared FAQ block — but neither "503A" nor "503B" appears anywhere checked, only vague category language about FDA-regulated suppliers and facilities.
Strengths
Names four fulfillment pharmacies directly, with address and phone number — more specific than most peers on this board that name a network or nothing at all
A single, plainly stated $239 price with no hedge language
Consistent pharmacy disclosure across its whole product line
Trade-offs
Despite naming four pharmacies, neither "503A" nor "503B" is stated for any of them anywhere on the site
The page does not make clear whether $239 is a one-time charge or a recurring monthly rate
yourEra's single-page pricing list quotes NAD+ at "from $249/mo" — the same no-pharmacy-named, no-category-stated shape as its tirzepatide row, and the highest NAD+ floor of any row on this board.
yourEra's single-page site states "NAD+: from $249/mo," the same layout as its tirzepatide and semaglutide lines, with no dose-tier breakdown or ceiling published.
Runs on the same single-page pricing list as yourEra's other compounds — no separate NAD+ product page. Medications are described only as "prepared and dispensed by state-licensed U.S. pharmacies," with no pharmacy named and no 503A/503B category stated.
Strengths
A straightforward single-page pricing list — no separate signup flow just to see the number
Medications are described as dispensed by state-licensed U.S. pharmacies, per its own homepage
Free shipping from its stated U.S. pharmacy network, the same claim as its other compounds
Trade-offs
The highest published NAD+ starting price on this board ($249/mo)
"From" pricing only — no dose-tier breakdown or ceiling is published
No pharmacy is named and no 503A/503B category is disclosed; state availability is not published as a list
Empower IS the compounding pharmacy, not a telehealth reseller — its own site states directly which two federal regulatory categories it operates under — but, as with every compound it sells, no price for NAD+ is published anywhere on its public site.
EP
No price is published on Empower's public site for NAD+. Its own FAQ states plainly that a figure exists only once an actual prescription is on file, the same no-public-price policy as its tirzepatide and sermorelin listings.
Unlike every other row on this board, Empower does not run a telehealth intake — its own "Getting Started" page requires a patient to already have a prescriber elsewhere before Empower will fill anything, including NAD+. No clinician visit is bundled into anything it sells.
Strengths
Genuinely is the compounding pharmacy — its own site states two federal regulatory categories directly, not a reseller naming a third party's
No markup from a telehealth middleman sits between the pharmacy and the patient
The clearest, most direct regulatory-category statement of any row on this board
Trade-offs
No price for NAD+ is published anywhere on the public site — silence, not a low number, is the honest finding here
Requires an existing prescription from a provider elsewhere; no consult is bundled
Not a fit for a reader who wants a single online signup flow — this is a pharmacy, not a telehealth company
Voxy carries a direct, unhedged "503A Licensed Pharmacy" credential on its product pages and names its specific pharmacy (VialsRX) on a separate compliance page — but its own /nad-plus page publishes no price at all.
VO
No price is published on Voxy's own /nad-plus page — a real gap, not a low number, and the same honest reading this site gives every null-price row.
NAD+ runs through the same trust-bar credential as Voxy's tirzepatide and semaglutide pages: a "503A Licensed Pharmacy" badge, with the specific pharmacy (VialsRX, Houston, TX) named on a separate /compliance page rather than the product page itself.
Strengths
A direct, unhedged "503A Licensed Pharmacy" credential on its own product pages
Names its specific fulfillment pharmacy (VialsRX) and its clinical partner on a dedicated /compliance page — more specific than most peers on this board
Consistent regulatory disclosure across its whole product line, not just this one compound
Trade-offs
No price is published anywhere on its /nad-plus page
No dosing frequency or format detail (injectable vs. other) is stated on the page
Vyora Wellness states, unhedged, exactly which federal regulatory category its licensed compounding pharmacies fall under — a direct category claim — but its own /product/nad/ page publishes no price at all.
VW
No price is published on Vyora Wellness's own NAD+ product page — a real gap, honestly recorded rather than estimated.
NAD+ runs through the same regulatory-category disclosure as Vyora Wellness's other compounds. Its own FAQ states directly, unhedged, "Vyora strictly works with licensed 503A compounding pharmacies in the United States" — though no specific pharmacy is named by name anywhere checked.
Strengths
States a direct, unhedged regulatory-category claim on its own FAQ
A real, dedicated NAD+ product page exists on the live site
Consistent regulatory disclosure across its whole product line
Trade-offs
No price is published anywhere on its NAD+ product page
No specific pharmacy is named by name anywhere checked
REMEVi's own homepage names four real partner pharmacies under an unhedged "503A" claim, but a separate page on the same site states a different product (semaglutide) is compounded by a facility under a DIFFERENT regulatory category — an unresolved, self-contradictory regulatory claim — and its NAD+ Injections page itself publishes no price.
RE
No price is published on REMEVi's own /nad-injections/ page — a real gap, and the same honest reading this site gives every null-price row.
REMEVi's own homepage states, unhedged, "Named pharmacy on every label — 503A," naming four pharmacies directly. But its tirzepatide page's own FAQ states a different product is compounded by "a 503B outsourcing facility registered with the FDA" — two of REMEVi's own pages disagreeing about its regulatory sourcing, the same finding already documented on its other board rows, so this stays an open contradiction rather than a confirmed regulatory-category pass.
Strengths
Names four real pharmacies directly, by name, city, and (for two of them) address — more specific than many peers on this board
A real, dedicated NAD+ Injections product page exists on the live site
States plainly that a pharmacy name is printed on every vial label — a checkable, patient-facing disclosure most peers don't offer
Trade-offs
No price is published anywhere on the NAD+ Injections page
Its own site states two DIFFERENT federal regulatory categories for two different products — a real, unresolved self-contradiction about its own sourcing
No dosing frequency or format detail beyond "Injections" is published
Direct Meds lists NAD+ among its compounds, but — like the rest of its catalogue — names no pharmacy and publishes no price anywhere on the pages we could reach.
DM
No price is published for NAD+ on Direct Meds' own site — a real gap, not a low number, and the same honest reading this site gives every null-price row.
NAD+ runs through the same generic disclosure as Direct Meds' other compounds. No pharmacy is named anywhere on the pages checked (homepage, /products/tirzepatide, /products/semaglutide, /products/sermorelin, FAQ). Its own FAQ states only that it works with "fully licensed pharmacies" and that prescriptions are compounded "at a certified U.S. pharmacy" — generic language, no name, no 503A/503B category stated.
Strengths
A real, live product listing exists for NAD+ on the site
Part of a broader, already-reviewed catalogue on this site (tirzepatide, sermorelin, semaglutide)
States generally that its pharmacies are licensed and certified, even without naming one
Trade-offs
No price is published anywhere for NAD+
No pharmacy is named anywhere on the pages checked, and neither "503A" nor "503B" appears
OrderlyMeds names three real pharmacies (SmartPharmaRx, Casa, PerfectRx) and separately states a regulatory-category claim in the same FAQ — but the two are never tied together in one sentence, and its own NAD+ product page publishes no price.
OR
No price is published on OrderlyMeds' own /treatments/longevity/nad/ page — a real gap, honestly recorded rather than estimated.
NAD+ has its own dedicated longevity product page. Its own FAQ states, in two separate sentences: "Yes, 503A pharmacies are licensed by state boards of pharmacy," then, "OrderlyMeds exclusively works with pharmacies based in the United States, including SmartPharmaRx, Casa, and PerfectRx/PerfectionRx." The two claims are never tied together in one sentence, so no specific named pharmacy is confirmed under that regulatory category here.
Strengths
Names three real pharmacy partners directly, by name, in its own FAQ
States a regulatory-category claim, even though it isn't directly tied to a specific named pharmacy in the same sentence
A real, dedicated NAD+ longevity product page exists on the live site
Trade-offs
No price is published anywhere on the NAD+ product page
Its regulatory-category claim and its three named pharmacies appear in separate sentences, never confirmed together
Ivim prices NAD+ at $129 for the first cycle plus a separate $75/mo membership fee — the same two-part pricing structure its tirzepatide and sermorelin rows already document — and names only a vague pharmacy category, never "503A" or "503B" outright.
Ivim's own /nad/ page prices NAD+ at "$129" for the initial order plus a recurring "$75/mo Membership" fee required to keep ordering — a two-part cost, not a single monthly figure.
NAD+ runs through the same membership-plus-treatment model as Ivim's other compounds. Its own /compounded-tirzepatide/ page (its clearest pharmacy statement sitewide) names only a vague category, "FDA-inspected, state-regulated compounding pharmacies" — neither "503A" nor "503B" appears anywhere checked, and no specific pharmacy is named.
Strengths
A published, itemized two-part price (order fee + membership) rather than a vague "starting at" floor
States a general regulatory-standard claim ("FDA-inspected, state-regulated") even without naming the specific category
Consistent pricing structure across its product line, not invented for this one compound
Trade-offs
The $75/mo membership fee is required on top of the $129 order price to keep ordering — the real ongoing cost is higher than the headline number alone suggests
Neither "503A" nor "503B" appears anywhere on the site, and no specific pharmacy is named by name
Bodybuilding Health+ prices NAD+ "starting at $129/mo" — one of the cheapest published NAD+ floors that carries no separate membership add-on — but its own Terms of Use describe fulfillment only as generic "independent third-party pharmacies," naming none.
BH
Bodybuilding Health+'s own site states NAD+ "Starting at $129/mo," with no dose-tier breakdown or ceiling published.
NAD+ runs through the same generic-pharmacy disclosure as Bodybuilding Health+'s other compounds. Its own Terms of Use state only, "All medications... are dispensed by independent third-party pharmacies" — plural, unnamed; neither "503A" nor "503B" appears anywhere checked.
Strengths
One of the lowest published NAD+ starting prices on this board, with no separate membership fee layered on top
A single, disclosed cash-pay price rather than a bundled program
Consistent, plain pricing structure across its product line
Trade-offs
"Starting at" pricing only — no dose-tier breakdown or ceiling is published
No pharmacy is named by name anywhere on the site, and neither "503A" nor "503B" is stated
Hone Health prices NAD+ at $165/mo on top of its required membership fee — the same membership-plus-treatment structure documented on its sermorelin row — and names no pharmacy anywhere on its longevity pages.
HH
Hone Health's own /mens/longevity/ page states NAD+ at "$165/mo + membership" — a treatment fee layered on top of Hone's separate, required membership plan, the same two-part pricing structure as its sermorelin listing.
NAD+ is one line item inside Hone Health's broader membership program. Neither its longevity pages nor its general Terms of Use name a compounding pharmacy, only stating twice, "This is a compounded product and has not been approved by the FDA" — the same pharmacy-silent pattern as its sermorelin row.
Strengths
A named operating entity (Time Therapeutics, Inc.) and several named affiliated medical practices in its Terms of Use
Membership includes a recurring lab panel (a 50+ biomarker panel every 3 months, per its own site) — not itemized for NAD+ specifically, but real lab infrastructure most peers don't offer
States plainly, twice, that the product is compounded and not FDA-approved, rather than implying otherwise
Trade-offs
$165/mo is on top of Hone's separate required membership fee — the all-in monthly cost is higher than the headline number alone suggests
No pharmacy is named anywhere on the longevity pages, the Terms of Use, or the how-it-works page
Committing to the membership is required to access NAD+ at all — there's no unbundled option
What determines a row's position is printed below, and nothing else moves it: a commercial relationship can earn a provider a disclosed, labelled placement, but it cannot change the criteria, the verified prices, or the drawbacks we print beside any row. The 3 factors below are what actually move a row up or down.
No price at all is the real finding
10 of the 38 providers here publish no price for NAD+ anywhere on their own site — not a low number, an absence, and we record it plainly as "Not published" rather than guessing at one. 22 more quote only a "starting at" or "as low as" floor, with no dose-tier breakdown of what a real order costs above it. Just 6 publish one flat, unhedged monthly (or per-order) rate.
Pharmacy sourcing, on the record or not
We only mark a provider's pharmacy chip with a regulatory facility category when its own site names the facility AND states that category — of the 38 providers here, 13 do. A striking number of the rest name specific pharmacies by name and address without ever tying them to "503A" or "503B" in the same sentence — a real, checkable gap, not an oversight on our part.
How the order is set
Any paid placement is marked Partner and listed first, as a disclosed commercial position — see the disclosure below the board. Within that group, and separately within every other row, the same rule applies: sorted by whether the provider clears the pharmacy-disclosure bar above, then by their own advertised price, low to high, for rows that tie. A provider's placement within its own group is never for sale.
Before you compare prices: unlike this site's tirzepatide and semaglutide boards — where a compounded version is sold specifically because an FDA-approved brand (Zepbound, Wegovy) is in shortage — NAD+ has no FDA-approved drug product of any kind. A direct DailyMed search returns no approved injectable NAD+ medication, only topical/cosmetic listings and a transdermal patch (checked live, August 2026). Every row on this board is a wellness/longevity product sold under a pharmacy's general compounding authority, not a stand-in for an approved drug awaiting a shortage resolution. What we score here is how honestly and clearly each provider states its price and pharmacy sourcing — not whether NAD+ itself is worth buying. Talk to a licensed clinician about that part.
Only confirmed NAD+ sellers are ranked here. Looking for a GLP-1 instead of a longevity compound? Our tirzepatide comparison and semaglutide comparison use the same pharmacy-first method against a related but not identical roster. Looking for a growth-hormone-axis peptide instead? Our sermorelin comparison uses the same method against a smaller roster still. Looking for a different longevity compound instead? Our Glutathione comparison shares 18 of its 19 providers with this one (only NuBloom sells Glutathione but not NAD+) — a provider selling NAD+ does not necessarily sell any of the other four compounds, and vice versa; see each board's own roster for what it actually confirmed.
Nothing on this page is medical advice. NAD+ is not an FDA-approved drug in any form we could find; every product on this board is sold as a compounded or wellness formulation under a pharmacy's general authority, not a medication reviewed by FDA for the safety or efficacy of this specific use. We read every price and sourcing claim on this page directly off each provider's own site by August 2026; providers change prices without telling us, so verify the current number before you buy. Ask a licensed clinician whether NAD+ fits your situation.
